20:44 , Jul 25, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute myelogenous leukemia (AML) Patient sample, cell culture and mouse studies suggest inhibiting SYNCRIP could help treat AML. In bone marrow samples from patients, SYNCRIP levels were higher than in hematopoietic stem and progenitor cells...
07:00 , Jul 21, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Methylenetetrahydrofolate dehydrogenase 2 (MTHFD2); MLL-AF9 fusion oncogene

Cancer INDICATION: Acute myelogenous leukemia (AML) Cell culture and mouse studies suggest inhibiting MTHFD2 could help treat AML. In human AML cell lines, shRNA targeting MTHFD2 decreased proliferation and colony formation compared with scrambled shRNA. In an...